KRYS News and Press, Krystal Biotech Inc. From 03/24/21

-  Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections -  Dr. Bhushan Hardas M.D., MBA appointed President, Jeune, Inc. PITTSBURGH, March 24, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal...

Krystal Biotech (KRYS): Q4 GAAP EPS of $0.53 beats by $0.05.Cash, cash equivalents and short-term investments of $271.3MPress Release For further details see: Krystal Biotech reports Q4 results

- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21. - Today announced Positive Opinion from the European Medicines Agency on Orphan Drug Designation for KB407 for the treatment of cystic fibrosis. - S...

PITTSBURGH, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer will be participating in a fireside chat ...

Moleculin Biotech (MBRX) -21% on launch of public offering.NTN Buzztime (NTN) -16%.PEDEVCO (PED) -13% after pricing stock offering.Ocugen (OCGN) -14%.Voyager Therapeutics (VYGR) -13% on termination of Parkinson’s collaboration with Neurocrine Bio.Titan Med...

Krystal Biotech (KRYS) has priced its public offering of ~1.9M common shares at $65.00/share, for expected gross proceeds of ~$125M.Underwriters' over-allotment is an additional 288,461 shares. Net proceeds will be used for development and commercialization of drug candidates; to complete dev...

PITTSBURGH, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock...

Krystal Biotech (KRYS) commenced a $100M underwritten public offering; underwriters granted 30-day option to purchase an additional 15% of the shares.Offer size, terms have not been disclosed.Proceeds along with cash and short-term investments to be used for completing the ongoing pivota...

Today, in a regulatory filing, Krystal Biotech ([[KRYS]] +1.6%) disclosed the key milestones expected for the company’s pipeline in the year ahead. The timeline includes four data readouts, one trial initiation, and a possible IND filing.With topline data expected in 2H 2021,...

Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L. Marantz, MD, PhD, MBA to its board of directors. “We are pleased t...